Cell Harvesting Market Size - Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

The global cell harvesting market covers equipment, consumables, and software used to separate and collect viable cells from tissues, blood, or culture systems. Industry analysts place the 2025 market size in a broad range, from roughly $6.71 billion to $9.0 billion depending on methodology, with the consensus clustering near $7.24 billion. Because no official government statistical agency publishes a standardized definition for this market, sizing estimates are derived from proprietary models, company disclosures, and academic funding data.

• •Estimated at approximately $7.24 billion in 2025 with a projected CAGR of about 13.4 percent
• •Market definition varies across research firms; no government agency publishes an official sizing figure
• •Sizing relies on proprietary top-down and bottom-up modeling using company revenues, grants, and academic investments

The primary catalyst for market expansion is the accelerating adoption of cell and gene therapies, which demand reliable, high-throughput cell isolation technologies. Automated harvesting systems that reduce manual handling, improve sterility, and comply with good manufacturing practice standards are displacing manual methods in both clinical and research settings. Additionally, robust stem cell research programs and increasing government grants for regenerative medicine are sustaining long-term demand.

• •Rising cell and gene therapy pipelines require scalable, reproducible cell harvesting solutions
• •Automation and closed-system processing are improving yield, purity, and regulatory compliance
• •Public funding initiatives and stem cell research investments are expanding the addressable market

The market is commonly segmented by product type, including manual and automated harvesting systems, as well as consumables such as filters, separation media, and collection bags. North America and Europe historically account for the largest shares due to established biotechnology infrastructure, strong regulatory frameworks, and high research spending. Asia-Pacific is emerging as the fastest-growing region, fueled by expanding clinical trial activity, rising healthcare investment, and growing biopharmaceutical manufacturing capacity.

• •Key product segments include manual systems, automated instruments, and associated consumables
• •North America leads in market share, supported by advanced research infrastructure and FDA-regulated clinical activity
• •Asia-Pacific is the fastest-expanding region, driven by growing biopharma manufacturing and clinical research investment

What are the recent trends and outlook?

The market is moving toward fully automated, closed systems that minimize contamination risk and support scalable production required for commercial cell therapies. Miniaturization and single-use technologies are gaining traction to reduce cross-contamination and simplify changeovers in multiproduct facilities. Over the forecast horizon, continued maturation of the cell therapy pipeline, combined with manufacturing cost pressures, is expected to sustain double-digit growth and drive consolidation in the sector.

• •Shift toward automated, closed-system platforms for GMP-compliant cell therapy manufacturing
• •Single-use and modular systems are increasingly adopted to reduce contamination and improve flexibility
• •Market projections suggest potential values between $13.2 billion and $20.1 billion by 2030-2035, depending on CAGR assumptions